Teva Pharmaceutical Industries Aktie
WKN: 883035 / ISIN: US8816242098
28.05.2025 05:19:00
|
Teva Gets FDA Fast Track Designation For Investigational Celiac Disease Drug TEV-53408
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced that the US Food and Drug Administration granted Fast Track designation for investigational TEV-53408, an anti-IL-15 antibody, for the treatment of people with celiac disease on a gluten-free diet.
TEV-53408 is currently being evaluated in a Phase 2a trial to assess the efficacy and safety in adults with celiac disease.
Fast Track is an FDA process designed to facilitate development and expedite review of drugs to treat serious conditions and address unmet medical needs.
TEV-53408 is an antibody designed to inhibit the activity of the cytokine, interleukin-15 (IL-15), to prevent intestinal damage and associated symptoms in individuals with celiac disease.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!